Legal Representation
Attorney
Patricia I. Reding
USPTO Deadlines
Application History
23 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Oct 28, 2025 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Sep 2, 2025 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Sep 2, 2025 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Aug 27, 2025 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jul 29, 2025 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jul 29, 2025 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Jul 29, 2025 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jul 29, 2025 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jul 29, 2025 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| May 29, 2025 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| May 29, 2025 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| May 29, 2025 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| Apr 23, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Apr 23, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Apr 23, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Feb 3, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Feb 3, 2025 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Feb 3, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jan 30, 2025 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jan 23, 2025 | TAEA | I | TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED | Loading... |
| Jan 23, 2025 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED | Loading... |
| Jan 15, 2025 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jul 22, 2024 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 001
Chemical preparations for use in the manufacture of pharmaceuticals; chemicals for use in the pharmaceutical industry; preservatives for use in the pharmaceutical industry; chemical additives for use in the manufacture of pharmaceuticals, namely, flavor improvers; biological preparations for use in the manufacture of pharmaceuticals and vaccines, namely, cell lines, cell culture media, antibodies, and proteins for use as intermediates for pharmaceuticals
Class 005
Pharmaceutical preparations for the treatment of viral diseases and disorders, immune diseases and disorders, respiratory diseases and disorders, microbial infections and diseases, cancer, haematological diseases and disorders, gastro-intestinal diseases and disorders, inflammation, arthritis, hepatitis, anemia, coagulation diseases and disorders, pain, obesity, and diabetes; vaccines; pharmaceutical preparations for skin care; none of the aforementioned products being finished pharmaceutical products administered to patients for the treatment of Parkinson's disease or other diseases or disorders of the central nervous system
Class 042
Scientific and technological services, namely, scientific research in the field of cell lines, cell cultures, proteins and antibodies for use in the development and manufacture of vaccines and pharmaceutical preparations; industrial analysis and research in the field of cell lines, cell cultures, proteins and antibodies for use in the development and manufacture of vaccines and pharmaceutical preparations; new product design services; pharmaceutical research services; pharmaceutical product evaluation; inspection of pharmaceuticals; testing of pharmaceuticals; pharmaceutical drug development services; development of pharmaceutical preparations and medicines; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; provision of scientific information in the field of vaccines, pharmaceuticals, and in the field of cell lines, proteins and antibodies for use in the manufacture and development of pharmaceuticals and vaccines; provision of toxicological research information; toxicology research services, namely, assessing toxicological information in relation to risks; chemical research, namely, assessing chemical information in relation to risks; none of the aforementioned services relating to finished pharmaceutical products administered to patients for the treatment of Parkinson's disease or other diseases or disorders of the central nervous system
Classification
International Classes
001
005
042